Rituximab immunotherapy for ocular adnexal lymphoma

Clinicopathologic correlation with 5-year follow-up

Jason A. Sokol, Leon C. Landau, Simeon A. Lauer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.

Original languageEnglish (US)
Pages (from-to)322-324
Number of pages3
JournalOphthalmic Plastic and Reconstructive Surgery
Volume25
Issue number4
DOIs
StatePublished - Jul 1 2009

Fingerprint

Immunotherapy
Lymphoma
Radiotherapy
Neoplasms
Mucous Membrane
Biopsy
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this

Rituximab immunotherapy for ocular adnexal lymphoma : Clinicopathologic correlation with 5-year follow-up. / Sokol, Jason A.; Landau, Leon C.; Lauer, Simeon A.

In: Ophthalmic Plastic and Reconstructive Surgery, Vol. 25, No. 4, 01.07.2009, p. 322-324.

Research output: Contribution to journalArticle

@article{86a909da6cf64dcaa3f6a007ef1c3959,
title = "Rituximab immunotherapy for ocular adnexal lymphoma: Clinicopathologic correlation with 5-year follow-up",
abstract = "Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.",
author = "Sokol, {Jason A.} and Landau, {Leon C.} and Lauer, {Simeon A.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1097/IOP.0b013e3181aadbb1",
language = "English (US)",
volume = "25",
pages = "322--324",
journal = "Ophthalmic Plastic and Reconstructive Surgery",
issn = "0740-9303",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Rituximab immunotherapy for ocular adnexal lymphoma

T2 - Clinicopathologic correlation with 5-year follow-up

AU - Sokol, Jason A.

AU - Landau, Leon C.

AU - Lauer, Simeon A.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.

AB - Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=69449106148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449106148&partnerID=8YFLogxK

U2 - 10.1097/IOP.0b013e3181aadbb1

DO - 10.1097/IOP.0b013e3181aadbb1

M3 - Article

VL - 25

SP - 322

EP - 324

JO - Ophthalmic Plastic and Reconstructive Surgery

JF - Ophthalmic Plastic and Reconstructive Surgery

SN - 0740-9303

IS - 4

ER -